Sensorion

Equities

ALSEN

FR0012596468

Biotechnology & Medical Research

Market Closed - Euronext Paris Other stock markets 10:46:00 2024-04-26 am EDT			5-day change	1st Jan Change
0.706 ^EUR	-0.56%		-1.12%	+64.19%

Apr. 08	Sensorion: completion of a private placement	CF
Apr. 05	Sensorion SA announced that it expects to receive ?15 million in funding	CI

Sensorion: partnership extended with Institut Pasteur

January 05, 2024 at 02:44 am EST

Biotech company Sensorion has announced a five-year extension of the research partnership framework agreement signed in 2019 with Institut Pasteur, involving its Institut de l'Audition research center.

This partnership grants Sensorion an option for exclusive licenses to develop and commercialize gene therapy drug candidates from collaborative projects to address unmet needs in hearing.

Two development programs are currently being conducted under this framework, namely SENS-501 (OTOF-GT) and GJB2-GT. Sensorion has submitted an application in July 2023 for SENS-501 to initiate a Phase 1/2 clinical trial in the UK and EU.

Copyright (c) 2024 CercleFinance.com. All rights reserved.

Go to the original article.
Legal disclaimer

Latest news about Sensorion

Sensorion: completion of a private placement	Apr. 08	CF
Sensorion SA announced that it expects to receive ?15 million in funding	Apr. 04	CI
Sensorion: study results in hearing loss	Mar. 11	CF
Sensorion Meets Primary Endpoint for Sens-401 Phase 2A Clinical Study for Residual Hearing Preservation	Mar. 11	CI
Sensorion SA Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 28	CI
Sensorion: completion of private placement	Feb. 09	CF
Sensorion Announces the Completion of Patient Inclusion in Phase 2A Clinical Trial of Sens-401 for Residual Hearing Preservation After Cochlear Implantation	Feb. 01	CI
Sensorion Appoints Federico Mingozzi as Non-Executive Director to the Board of Directors	Jan. 25	CI
Sensorion Extends Maturity of Pre-funded Warrants Issued to Redmile Group	Jan. 25	MT
Sensorion Receives Go-ahead in France for Phase 1/2 Clinical Trial of Hearing Impairment Treatment	Jan. 19	MT
Sensorion: clinical trial approved	Jan. 19	CF
Sensorion Announces Approval to Initiate Lead Gene Therapy Candidate Sens-501 into a Phase 1/2 Clinical Trial in Some European Countries	Jan. 19	CI
Sensorion: partnership extended with Institut Pasteur	Jan. 05	CF
Sensorion Extends Partnership Framework Deal with Institut Pasteur	Jan. 05	MT
Sensorion Announces Partnership with the Institut Pasteur to Accelerate Gene Therapy Programs Targeting Hearing Disorders	Jan. 05	CI
Sensorion: favorable safety profile in phase 2a trial	Dec. 18	CF
Sensorion appoints Director of Technical Operations	Dec. 12	CF
Sensorion SA Appoints Bernd Schmidt as New Chief Technical Officer	Dec. 12	CI
Sensorion SA Reports Earnings Results for the Half Year Ended June 30, 2023	23-09-20	CI
Sensorion SA announced that it has received ?33.214286 million in funding from Sofimac Innovation SAS, The Invus Group, LLC, Redmile Group, LLC	23-09-19	CI
HC Wainwright Initiates Sensorion with Buy Rating	23-09-07	MT
SENSORION : H.C. Wainwright initiates buy coverage	23-09-07	CF
Sensorion: €35 million private placement	23-08-04	CF
Sensorion to Raise EUR35 Million via Private Placement	23-08-04	MT
Sensorion SA announced that it expects to receive ?33.214286 million in funding from Sofimac Innovation SAS, The Invus Group, LLC, Redmile Group, LLC	23-08-02	CI

Chart Sensorion

Duration

Period

More charts

Company Profile

Sensorion is a clinical-stage biotech company, that specializes in the development of novel therapies to restore, treat and prevent hearing loss disorders, a significant global unmet medical need. Sensorion has built a R&D technology platform to expand its understanding of the pathophysiology and etiology of inner ear related diseases, enabling it to select the best targets and modalities for drug candidates. Its clinical-stage portfolio includes one Phase 2 product: SENS-401 (Arazasetron) progressing in a proof of concept (PoC) clinical study in cisplatin-induced ototoxicity (CIO) and, with partner Cochlear Ltd, in a study in patients scheduled for cochlear implantation. Sensorion has entered into a strategic collaboration with Institut Pasteur. It has two gene therapy programs, at preclinical stage, aimed at correcting hereditary forms of deafness including deafness caused by a mutation of the gene encoding for Otoferlin, and hearing loss related to mutation in GJB2 gene.

Sector

Biotechnology & Medical Research

Calendar

2024-09-18 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Sensorion

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.706 EUR

Average target price

2.375 EUR

Spread / Average Target

+236.40%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
SENSORION	+64.19%	208M
IQVIA HOLDINGS INC.	+1.51%	42.75B
MODERNA, INC.	+8.57%	41.34B
LONZA GROUP AG	+49.22%	41.61B
CELLTRION, INC.	-12.36%	26.59B
ICON PUBLIC LIMITED COMPANY	+8.92%	25.49B
ALNYLAM PHARMACEUTICALS, INC.	-25.13%	18.12B
MEDPACE HOLDINGS, INC.	+29.17%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.12%	11.76B
UNITED THERAPEUTICS CORPORATION	+6.35%	11B

Other Biotechnology & Medical Research